The Library
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
Tools
Tools
Tools
Connock, Martin, Armoiry, Xavier, Tsertsvadze, Alexander, Melendez-Torres, G. J., Royle, Pamela, Andronis, Lazaros and Clarke, Aileen (2019) Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. BMC Cancer, 19 (1). doi:10.1186/s12885-019-5507-6
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1186/s12885-019-5507-6
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Divisions: | Faculty of Medicine > Warwick Medical School | ||||
| Journal or Publication Title: | BMC Cancer | ||||
| Publisher: | BioMed Central | ||||
| ISSN: | 1471-2407 | ||||
| Official Date: | 2019 | ||||
| Dates: |
|
||||
| Volume: | 19 | ||||
| Number: | 1 | ||||
| DOI: | 10.1186/s12885-019-5507-6 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
